

Claim Amendments

Claim 1-40 (Withdrawn)

Claim 41 (Currently Amended): A method of treating an allergy in a mammal, said method comprising administering to said mammal ~~at least one ingredient selected from the group consisting of an anti-IgE antibody, an anti-IgE receptor antibody, a soluble IgE receptor, an anti-interleukin receptor antibody, a soluble interleukin receptor, an anti-interferon-alpha antibody, an anti-interferon-alpha receptor antibody, a soluble interferon-alpha receptor, an anti-histamine antibody, an anti-histamine receptor antibody, a soluble histamine receptor, an anti-leukotriene antibody, an anti-leukotriene receptor antibody, and a soluble leukotriene receptor,~~ wherein said interleukin is at least one interleukin involved in the production of IgE in a mammal, thereby treating an allergy in a mammal.

Claim 42 (Cancelled)

Claim 43-44 (Withdrawn)

Claim 45 (Original) The method of claim 41, said method further comprising administering interferon gamma to said mammal.

Claim 46-52 (Withdrawn)

Claim 53 (Currently Amended): A kit for treating an allergy in a mammal, said kit comprising ~~an at least one ingredient selected from an anti-IgE antibody, an anti-IgE receptor antibody, a soluble IgE receptor, an anti-interleukin receptor antibody, a soluble interleukin receptor, an anti-interferon-alpha antibody, an anti-interferon-alpha receptor antibody, a soluble interferon-alpha receptor, an anti-histamine antibody, an anti-histamine receptor antibody, a soluble histamine receptor, an anti-leukotriene antibody, an anti-leukotriene receptor antibody, and a soluble leukotriene receptor,~~ wherein said interleukin is at least one interleukin involved in the production of IgE in a mammal, an applicator, and an instructional material for the use thereof.

Claim 54 (Original): The kit of claim 53, said kit further comprising interferon gamma.

Claim 55-61 (Withdrawn)

Claim 62 (Currently Amended): A method of inhibiting production of IgE in a mammal, said method comprising administering to a mammal ~~at least one ingredient selected from the group consisting of an anti-IgE antibody, an anti-IgE receptor antibody, a soluble IgE~~

receptor, an anti-interleukin receptor antibody, a soluble interleukin receptor, an anti-interferon alpha antibody, an anti-interferon alpha receptor antibody, a soluble interferon alpha receptor, an anti-histamine antibody, an anti-histamine receptor antibody, a soluble histamine receptor, an anti-leukotriene antibody, an anti-leukotriene receptor antibody, and a soluble leukotriene receptor, wherein said interleukin is at least one interleukin involved in the production of IgE in a mammal, thereby inhibiting production of IgE in a mammal.

Claim 63: (Cancelled)

Claim 64: (Original) The method of claim 63, said method further comprising administering interferon gamma to said mammal.

Claim 65-71: (Withdrawn)

Claim 72: (Currently Amended) A kit for inhibiting production of IgE in a mammal, said kit comprising at least one ingredient selected from an anti-IgE antibody, an anti-IgE receptor antibody, a soluble IgE receptor, an anti-interleukin receptor antibody, a soluble interleukin receptor, an anti-interferon alpha antibody, an anti-interferon alpha receptor antibody, a soluble interferon alpha receptor, an anti-histamine antibody, an anti-histamine receptor antibody, a soluble histamine receptor, an anti-leukotriene antibody, an anti-leukotriene receptor antibody, and a soluble leukotriene receptor, wherein said interleukin is at least one interleukin involved in the production of IgE in a mammal, an applicator, and an instructional material for the use thereof.

Claim 73: (Original) The kit of claim 72, said kit further comprising interferon gamma.

Claim 80: (Currently Amended) A kit for treating an allergy in a mammal, said kit comprising a pharmaceutical composition comprising at least one a protein in an amount effective for treating an allergy in a mammal in a pharmaceutically acceptable carrier, wherein said protein is selected from an anti-IgE antibody, an anti-IgE receptor antibody, a soluble IgE receptor, an anti-interleukin receptor antibody, a soluble interleukin receptor, an anti-interferon alpha antibody, an anti-interferon alpha receptor antibody, a soluble interferon alpha receptor, an anti-histamine antibody, an anti-histamine receptor antibody, a soluble histamine receptor, an anti-leukotriene antibody, an anti-leukotriene receptor antibody, and a soluble leukotriene receptor, wherein said interleukin is at least

~~one interleukin involved in the production of IgE in a mammal~~, an applicator, and an instructional material for the used thereof.

Claim 81: (Original) The kit of claim 80, said kit further comprising interferon gamma.

Claim 82-87: (Withdrawn)

Claim 88: (Currently Amended) A pharmaceutical composition comprising ~~at least one~~ a protein in an amount effective for treating an allergy in a mammal, wherein said protein is ~~selected from the group consisting of an anti-IgE antibody, an anti-IgE receptor antibody, a soluble IgE receptor, an anti-interleukin receptor antibody, a soluble interleukin receptor, an anti-interferon-alpha antibody, an anti-interferon-alpha receptor antibody, a soluble interferon-alpha receptor, an anti-histamine antibody, an anti-histamine receptor antibody, a soluble histamine receptor, an anti-leukotriene antibody, an anti-leukotriene receptor antibody, and a soluble leukotriene receptor~~, wherein said interleukin is ~~at least one interleukin involved in the production of IgE in a mammal~~, in a pharmaceutically acceptable carrier.

Claim 89: (Original) The pharmaceutical composition of claim 88, said composition further comprising interferon gamma.

Claim 90-94: (Withdrawn)

Claim 95: (Currently Amended) A method of treating bronchial asthma in a human, said method comprising administering to a human ~~at least one ingredient selected from the group consisting of an anti-interferon-alpha antibody, an anti-interferon-alpha receptor antibody, and a soluble interferon-alpha receptor~~, an anti-histamine antibody, thereby treating bronchial asthma in a human.

Claim 96-97: (Cancelled)

Claim 98: (Currently Amended) The method of claim 97 ~~95~~, said method further comprising administering interferon gamma to said human.

Claim 99: (Cancelled)

Claim 100: (New) The method of claim 41 wherein said mammal is a human.

Claim 101: (New) The method of claim 62 wherein said mammal is a human.

Summary

Applicants respectfully submit that the present Amendment adds no new matter, and the pending claims are in condition for Examination. Favorable examination of the claims on the merits is respectfully requested at this time.

Respectfully submitted,

BORIS SKURKOVICH ET AL.

August 6, 2003
Date)

By:

Kathryn Doyle
KATHRYN DOYLE, Ph.D., J.D.
Registration No. 36,317
MORGAN, LEWIS & BOCKIUS, L.L.P.
1701 Market Street
Philadelphia, PA 19103
Telephone: (215) 963-5000
Direct Dial: (215) 963-4723
Facsimile: (215) 963-5001
E-Mail: kdoyle@morganlewis.com

KD/JDGB

Enclosures: Petition for Three-Month Extension of Time with Fee Authorization
Response to Restriction Requirement